Cardiol Therapeutics Inc. (CRDL)

NASDAQ: CRDL · IEX Real-Time Price · USD

2.060

+0.050 (2.49%)

At close: May 1, 2024, 4:00 PM

2.059

-0.001 (-0.05%)

After-hours: May 1, 2024, 5:37 PM EDT

Cardiol Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	0	0	0.08	0	0
Gross Profit	0	0	0.08	0	0
Selling, General & Admin	15.56	22.37	27.87	10.09	7.18
Research & Development	14.22	18.96	10.87	10.6	3.53
Other Operating Expenses	0	0	0	0	3.42
Operating Expenses	29.79	41.34	38.74	20.69	14.13
Operating Income	-29.79	-41.34	-38.66	-20.69	-14.13
Other Expense / Income	-1.66	-10.41	-7.03	-0.05	-0.44
Pretax Income	-28.13	-30.93	-31.64	-20.64	-13.68
Net Income	-28.13	-30.93	-31.64	-20.64	-13.68
Shares Outstanding (Basic)	64	63	43	30	26
Shares Outstanding (Diluted)	64	63	43	30	26
Shares Change	3.13%	44.61%	44.77%	15.63%	-
EPS (Basic)	-0.44	-0.49	-0.73	-0.69	-0.53
EPS (Diluted)	-0.44	-0.49	-0.73	-0.69	-0.53
Free Cash Flow	-25.24	-27.3	-23.55	-9.17	-11.8
Free Cash Flow Per Share	-0.39	-0.44	-0.55	-0.31	-0.46
Gross Margin	-	-	100.00%	-	-
Operating Margin	-	-	-49091.93%	-	-
Profit Margin	-	-	-40170.45%	-	-
Free Cash Flow Margin	-	-	-29904.22%	-	-
EBITDA	-27.88	-30.71	-31.42	-20.41	-13.53
EBITDA Margin	-	-	-39890.58%	-	-
Depreciation & Amortization	0.25	0.22	0.22	0.23	0.15
EBIT	-28.13	-30.93	-31.64	-20.64	-13.68
EBIT Margin	-	-	-40170.45%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).